2.1 Study samples
A total of 18 ISH&ACI patients were recruited from the Affiliated Hospital of Shandong University of Traditional Chinese Medicine from May 2019 to April 2020. Isolated systolic hypertension and atherosclerotic cerebral infarction were defined according to the 2018 revised edition of the Chinese guidelines for the prevention and treatment of hypertension (exposure draft) and 2015 China Cerebrovascular Disease Classification. Meanwhile, subjects conforming to the following standards were included: 1. aged 18 years old or above, no gender limitations; 2. within 2 weeks to 6 months after the occurrence of cerebral infarction; 3. willing to participate in this experiment and cooperate with the doctors and sign the informed consent in writing. A total of 18 isolated systolic hypertension (ISH) controls were recruited from the same hospital during the same period. 8 ISH&ACI patients and 8 ISH controls were randomly selected from 18 ISH&ACI patients and 18 ISH controls for RNA sequencing, and the remaining samples were used as replication population for the validation of differentially expressed lncRNAs and mRNAs.
The study protocol was approved by the Ethics Committee of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine in Shandong, China. Written informed consent was obtained from all patients or their families under the Declaration of Helsinki.
2.4 Cell
Cell culture: HBMECs (Hunan Fenghui Biotechnology Co.Ltd,Cat.CL0116) were cultured with high glucose’s (4.5 mg/ml) Dulbecco’s Modified Eagle Medium (DMEM, Gibco, REF.#C11995065BT) and supplemented with 10% Fetal Bovine Serum (FBS, Gibco, REF.10099141) and 1% Penicillin/Streptomycin solution (P/S, HyClone, Cat. #SV30010) at 37°C in a humidified 5% CO2 incubator. Then, HBMECs were intervened by Sodium pyruvate solution Ang II (Solarbio Co., Ltd., Beijing, China) and OGD/R (Oxygen-Glucose Deprivation/Reoxygenation). HBMECs of exposed into AngⅡ and normoxia were served as controls.
MTT assay: The effect of AngⅡ and OGD/R on proliferation were detected by MTT assay. HBMECs were seeded at a density of 1500 cells per well into 96-well microplates in a final volume of 100 µL with 2×10− 6mol/L of AngⅡ, and they were maintained for 12, 24, 48, or 72 hours at 37°C in a humidified atmosphere containing 5% CO2. After that, HBMECs were cultured in Earle's Balanced Salt Solution (EBSS, Solarbio, Cat.H2025) without glucose and fetal bovine serum and deprived-oxygen by transferring into an anaerobic incubator (0% O2/5%CO2/95%N2) for 4 hours. After OGD, cells were returned to a normoxic incubator under 5% CO2/95% air for 24 hours in complete medium. Subsequently, to monitor cell viability, 10 µl of sterile 3-(4,5-dimethylthiazol-2-yl)-2,5-Diphenyl-2H-tetrazolium bromide dye (MTT; Solarbio, Lot.#303H0525, Beijing, China) at a final concentration of 5mg/ml was added to each well for incubation at 37°C for 4h; this was followed by the administration of 150 µl dimethyl sulfoxide solution (DMSO; Sinopharm Chemical Reagent Co., Ltd, Cat. #30072418, Shanghai, China) per well to dissolve the formazan crystals. The optical density value (OD-value) was measured at 562nm using a Multiskan GO microplate reader (Thermo Scientifific, Waltham, MA, USA) according to the manufacturer's instruction. The OD-value indicates the counts of living cells.
Apoptosis rate assay: The effect of AngⅡ and OGD/R on apoptosis rate was assessed using Annxin V staining by Muse Cell Analyer(Germany Merck&Millipore), according to the manufacturer's direction.
qRT-PCR: To validate the sequence data, 11 DE genes related to endothelial dysfunction were chosen for qRT-PCR, including 8 lncRNAs (ENST00000565493,ENST00000606054,ENST00000590604,NONHSAT138949.2, ENST00000566942, ENST00000369385, NONHSAT217189.1, ENST00000540082) and their corresponding target mRNAs (CD226,PARVB). After being cultured in 6-well plates at a density of 6000 cells/cm2, total RNAs from model cells and control cells were extracted using SPARKeasy Improved Tissue/Cell RNA Kit (HAOSAIL, Lot.YADKZ). PrimeScript™ RT reagent Kit with gDNA Eraser (Perfect Real Time) (TaKaRa, Cat.#RR047A) and reverse transcription reaction according to thestandard operation process provided by the manufacturer was used to synthesize the DNA template. TB Green™ Premix Ex Taq™ II (Tli RNaseH Plus) (TaKaRa, Cat.#RR820A) was used to amplify qRT-PCR following the manufacturer’sinstructions. LncRNAs expression was normalized to GAPDH as described inthe literature. Complementary DNA was synthesized using a Transcriptor First Strand cDNA Synthesis Kit (Roche, Cat. #04379012001, Germany), and qRT-PCR was performed by using LightCycler 480 SYBR Green I Master (Roche, Cat. #04707516001), according to the manufacturer’s instructions, using a LightCycler480 instrument (Roche). The primer sequences are listed in SupplementaryTable 1 (Sangon Biotech, Shanghai, China). The data were calculated and presented by the 2−ΔΔCT method.